Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?

doi:10.1016/j.beha.2017.09.006

Back to search

Article

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?

Best practice & research. Clinical haematology - 1 Dec 2017

Stone Richard M

Abstract excerpt

For 4 decades, new agents had not been permanently approved for use in treating acute myeloid leukemia (AML). The long dry spell was broken in 2017, however, with the approval of several agents: midostaurin for addition to chemotherapy in mutant FLT3 patients undergoing intensive chemotherapy, en...

Topics

Aminoglycosides
Antibodies, Monoclonal, Humanized
Gemtuzumab
Humans
Isocitrate Dehydrogenase
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Staurosporine
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.